Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (22)

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  2. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 18, pp. 3744-3758

  3. NanoString analysis of mycosis fungoides reveals individual molecular identity

    British Journal of Dermatology

2022

  1. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial

    The Lancet Haematology, Vol. 9, Núm. 6, pp. e425-e433

  2. Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

    BMC Cancer, Vol. 22, Núm. 1

  3. Progression to lung fibrosis in severe COVID-19 patients: A morphological and transcriptomic study in postmortem samples

    Frontiers in Medicine, Vol. 9

  4. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177

  2. Follow-up study confirms the presence of gastric cancer dna methylation hallmarks in high-risk precursor lesions

    Cancers, Vol. 13, Núm. 11

  3. Lung Cancer in Spain

    Journal of Thoracic Oncology

  4. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer

    Archives of Pathology and Laboratory Medicine, Vol. 145, Núm. 8, pp. 1031-1040

2020

  1. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens

    Cancer Cytopathology, Vol. 128, Núm. 12, pp. 928-938

  2. Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features

    Cancer Research, Vol. 80, Núm. 4, pp. 843-856

  3. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  4. Cystic brain metastases revealed patient with RET-rearranged non–small-cell lung cancer with leptomeningeal carcinomatosis and RET-positive in CSF

    JCO Precision Oncology, Vol. 4

  5. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy

    EBioMedicine, Vol. 53

  6. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

2019

  1. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy

    Journal of Thoracic Oncology, Vol. 14, Núm. 4, pp. 641-655